Most people need to take Plavix (clopidogrel) for at least 6 to 12 months after receiving a stent, depending on why the stent was placed and the type of stent used. The exact duration is a balancing act between preventing a blood clot from forming inside the stent and minimizing bleeding risk, so your timeline may be shorter or longer than the standard recommendation.
Why Plavix Matters After a Stent
When a stent is placed inside a coronary artery, the metal mesh sits directly in contact with your bloodstream. Your body recognizes it as foreign, and platelets (the blood cells responsible for clotting) tend to stick to the stent struts. Plavix works by blocking a specific signal that tells platelets to clump together, which dramatically lowers the chance of a clot forming inside the stent. This type of clot, called stent thrombosis, can cause a heart attack.
Plavix is always taken alongside low-dose aspirin during this period. The combination is called dual antiplatelet therapy, or DAPT. Together, the two drugs shut down clotting through different pathways, offering stronger protection than either one alone.
Standard Timelines by Situation
The recommended duration depends primarily on two things: the reason you needed a stent and the type of stent you received.
After a heart attack or acute coronary syndrome: The 2025 guidelines from the American College of Cardiology and American Heart Association recommend 12 months of DAPT as the default for patients without high bleeding risk. This is the most common scenario, and the one-year mark has been the standard of care for years.
Stable heart disease with a drug-eluting stent: If your stent was placed for a blockage that wasn’t causing a heart attack, the minimum recommended course is 6 months. Drug-eluting stents release medication that helps prevent the artery from narrowing again, but they take longer for the artery lining to fully grow over the metal struts, which is why they require a longer course of Plavix than bare-metal stents.
Bare-metal stents: These older stents require a minimum of just 1 month of Plavix. The artery lining covers bare-metal stents more quickly, so the window of highest clot risk is shorter. Bare-metal stents are less commonly used today, but they’re still placed in certain situations, particularly when a patient needs surgery soon and can’t stay on blood thinners for months.
When the Timeline Gets Shorter
Recent guidelines have opened the door to shorter courses for certain patients. For people who had an acute coronary event but have gone 1 to 3 months without any complications and aren’t at high risk for another clot, stepping down to Plavix alone (dropping the aspirin) is now considered a reasonable option. For patients with high bleeding risk, the course may be shortened to as little as 1 month after an acute event.
If you’re already taking a blood thinner for another condition, such as atrial fibrillation, the guidelines recommend an abbreviated DAPT course of just 1 to 4 weeks, followed by continuing your blood thinner alongside a single antiplatelet drug (typically Plavix rather than aspirin). The combination of a blood thinner plus two antiplatelet drugs raises bleeding risk significantly, so doctors try to minimize the overlap.
When the Timeline Gets Longer
Some patients benefit from staying on DAPT beyond 12 months. The American College of Cardiology developed a scoring tool called the DAPT Score to help determine whether the benefits of extended therapy outweigh the bleeding risks. It’s designed for patients who have already completed 12 months without a major bleed or clot.
The score factors in your age, whether you have diabetes, a history of smoking, prior heart attacks, heart failure, high blood pressure, kidney problems, or peripheral artery disease. Procedural details matter too, including whether the stent was placed during a heart attack, whether it went into a bypass graft, and how small the stent diameter was. A score of 2 or higher suggests that continuing DAPT is likely worth the trade-off. Below 2, the added bleeding risk tends to outweigh the benefit.
What Happens If You Stop Too Early
Stopping Plavix before the recommended course finishes is one of the strongest risk factors for stent thrombosis. A study comparing patients who stopped within the first year found that those who quit within 3 months had a major cardiac event rate of about 10%, compared to roughly 1% in patients who continued their full course with first-generation stents. Even with newer second-generation drug-eluting stents, which are safer overall, stopping early was linked to higher rates of death and major cardiac events.
The absolute risk of stent thrombosis is low, but when it happens, it’s a medical emergency. If cost, side effects, or an upcoming procedure makes you consider stopping, talk to your cardiologist first. There is almost always a way to manage the situation without abruptly discontinuing the drug.
Plavix and Upcoming Surgery
If you need elective surgery while on Plavix, the standard recommendation is to stop the drug at least 5 days before the procedure. That window gives your body enough time to produce new, fully functional platelets. This is one reason doctors try to delay non-urgent surgeries until after the minimum DAPT period is complete.
For patients who need emergency surgery, the timing creates a difficult tradeoff between surgical bleeding and stent clotting. In those cases, the surgical and cardiology teams coordinate closely to find the safest approach.
What You Take After Plavix Ends
Once your Plavix course is complete, you won’t stop antiplatelet therapy entirely. The traditional practice has been to continue low-dose aspirin indefinitely for secondary prevention of heart disease. However, newer evidence is shifting that picture. A large trial with 5-year follow-up found that continuing Plavix alone (without aspirin) as the long-term maintenance drug led to better cardiovascular outcomes without increasing bleeding, at least in East-Asian populations. This approach is gaining traction, though aspirin monotherapy remains the more established standard in most guidelines.
Regardless of which single agent you end up on, the key point is that some form of antiplatelet therapy typically continues for life after a coronary stent. The DAPT period is the intensive phase, and what follows is lower-intensity, long-term protection.